Home › Trial NCT03281382
Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
- Trial IDNCT03281382
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorHenry Ford Health System
- Enrollment12
- Start date2017-07-01
- ConditionsMetastatic Pancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.